1. Introduction {#sec1}
===============

Cardiovascular disease is the first cause of death in the developed world. Its main feature is the extensive presence of atherosclerosis, which is anticipated by morphologic and functional changes involving vessel wall and vascular endothelium. Impairment of functional properties of the arteries is strictly related to the morphologic changes in vessel structure and to the alteration in mechanical properties \[[@B1], [@B2]\]. Endothelial dysfunction is characterized by impaired endothelium-dependent vasodilation and "endothelial activation," which is associated with a proinflammatory and procoagulatory milieu that promotes development and progression of vascular disease \[[@B3], [@B4]\]. Cardiovascular risk factors are closely linked to the development of endothelial dysfunction and arterial wall stiffness, which are significant predictors of cardiovascular risk and mortality \[[@B5], [@B6]\]. A synergistic interplay exists among the anatomic structures of the vessel wall, the vascular endothelium, endothelial-derived factors, and circulating cytokines, and such interplay promotes the development of overt atherosclerosis.

Omega-3 polyunsaturated fatty acids (n-3 PUFA) have shown the potential to beneficially impact fundamental steps involved in the development of preclinical atherosclerosis \[[@B7]\]. By targeting arterial stiffness and endothelial dysfunction, administration of n-3 PUFA may prevent atherosclerosis and cardiovascular disease. A wide range of molecular and physiological pathways are affected by n-3 PUFA administration and are involved in the regulation of arterial stiffness and endothelial dysfunction.

This review will focus on the complex nature of arterial stiffness and endothelial dysfunction and on the translational potential of n-3 PUFA for treating vascular remodeling.

2. Structural and Mechanical Properties of the Arterial Wall {#sec2}
============================================================

Arterial wall consists of a complex morphological organization, with multiple layers designed to maintain the fundamental properties of blood carrying and blood pressure regulation. This structure is aimed at maintaining the elastic properties of the arterial wall, which are important for the physiological vascular function \[[@B8]\]. The distensibility of arterial vessels determines the amplitude of pulse pressure as well as the speed of the propagating pulse wave in the arterial system. The loss of elastic properties leads to arterial stiffness, a parameter that has been recognized in recent years as an intermediate endpoint for cardiovascular morbidity and mortality, independently of conventional risk factors for cardiovascular disease \[[@B9]\]. Arterial stiffening or arteriosclerosis, which is caused by the loss of the medial arterial load bearing components of the arterial wall, is pathologically distinct from the obstructive condition of arteries or atherosclerosis, usually defined as the deposition of lipids, white blood cells, and calcium in the arterial wall \[[@B10]\], although these two conditions are closely intertwined \[[@B11]\]. Arteriosclerosis could directly promote cardiovascular disease, by increasing pulsatile load on heart, reducing myocardial blood flow, damaging small vessels in kidney or brain, and by promoting atherogenesis through a reduction in shear stress rate. On the other hand, the presence of atherosclerotic plaques could mechanically alter the properties of the arterial wall.

The assessment of arterial stiffness has been increasingly used in clinical setting, considering its good predictive value for cardiovascular events. A large number of studies have been addressed to understand the mechanisms and factors influencing the development of arterial stiffness and to report interventions able to influence arterial wall properties \[[@B9]\]. Reducing arterial stiffness may be useful to reduce incidence of cardiovascular events and mortality; thus evidence-based treatments would be clinically important, but currently a specifically designed therapeutic strategy for this purpose has not yet been defined. Dietary habits are well-known determinants of the vascular changes occurring in the arterial wall with age, and many studies have focused on the effects of pharmacologic and nonpharmacologic interventions to modulate arterial elastic properties \[[@B12]\].

3. Effects of n-3 PUFA on Atherogenesis {#sec3}
=======================================

A large body of evidence demonstrates the substantial benefits of n-3 PUFA in atherogenesis \[[@B13]\]. n-3 PUFA play several important roles in cellular molecular mechanisms, tissue metabolism and regulation, and act as pleiotropic agents on the cardiovascular system \[[@B14]\]. The mechanisms through which n-3 PUFA interfere with atherogenesis are therefore multiple. Their effect on endothelial dysfunction, oxidative stress, and inflammation, causing the onset of atherogenesis, will be discussed in the next section. The antiatherogenic effect of n-3 PUFA on serum lipid profile, with a reduction in both triglycerides and very-low-density lipoproteins, is well known and has recently been reviewed \[[@B15], [@B16]\]. However, it is unclear as to how many of cardiovascular benefits are related to n-3 PUFA lipid lowering effects and how many of them are due to lipid-independent effects.

Regarding the lipid deposition in the arterial layers, which is associated with atherogenesis \[[@B17]\], in a mouse animal model, n-3 PUFA were able to protect the arterial wall by decreasing the LDL uptake and by directing lipid deposition away from the aortic media, by decreasing the lipoprotein lipase expression \[[@B18]\]. This antiatherogenic effect is also associated with a reduction of macrophages and other proinflammatory markers and is enhanced by an incremental replacement of n-3 PUFA in the diet \[[@B19]\].

The proliferation of vascular smooth muscle cells and their lipid accumulation are associated with early lesion in the arterial wall and atherosclerosis promotion \[[@B20]\], highlighting the role of these cells in the pathophysiology of vascular remodeling \[[@B21]\]. An effect of n-3 PUFA on vascular smooth muscle cells activation has been reported in several studies. In culture cells, EPA and DHA were incorporated into phospholipids and slow down the progression of cell cycle, by inhibiting DNA synthesis and replication, thus suppressing vascular smooth muscle cells proliferation \[[@B22]\]. A similar inhibition in the proliferation of vascular smooth muscle cells was observed in human coronary arteries after consumption of fish oil, with a regulation of adhesion molecules on these cells \[[@B23]\].

A specific effect of n-3 PUFA on plaque stability has also been reported, in preventing the rupturing of vulnerable plaques, that leads to arterial thrombosis and obstruction. This effect could explain the reduction in cardiovascular endpoints observed in short-term trials conducted with n-3 PUFA. In patients undergoing carotid endarterectomy, atherosclerotic plaques revealed reduced macrophages infiltration and more stable morphology after n-3 PUFA administration \[[@B24]\]. In a more recent study, in plaques of patients supplemented with n-3 PUFA analyzed after carotid endarterectomy, reduced inflammation and significantly lower levels of mRNA for matrix metalloproteinases were observed \[[@B25]\].

The evaluation of intima-media thickness (IMT) has long been used as a marker of atherosclerotic involvement of arterial walls and as a surrogate endpoint of cardiovascular disease \[[@B26]\]. Although several observational studies reported an inverse association of n-3 PUFA administration, as diet consumption or fish oil administration, a systemic review of human intervention studies could not draw a firm conclusion on the effects of n-3 PUFA administration on IMT \[[@B27]\]. Also more recent trials were inconclusive: a positive effect on IMT was observed in patients with type 2 diabetes \[[@B28]\], although, in elderly men with hypercholesterolemia, a favorable effect on IMT progression was not confirmed, whereas n-3 PUFA imposed an improvement in arterial elasticity \[[@B29]\]. Recent cross-sectional studies reported that DHA levels, but not EPA, have an inverse association with IMT, suggesting that DHA may have a more potent antiatherogenic effect than EPA, independently of other risk factors \[[@B30]\].

4. Influence of n-3 PUFA on Arterial Wall Stiffening {#sec4}
====================================================

As above mentioned, the alteration of mechanical properties of the arterial wall is strictly connected with atherosclerothic involvement. An increased plaque burden and a modification in the composition of arterial layers can hamper arterial elastic behavior. Nevertheless, although sharing some common risk factors, these two processes should be considered separately. While effects of n-3 PUFA on atherogenesis, on atherosclerotic plaques stability, and on arterial restenosis have been previously extensively reviewed, we will focus on n-3 PUFA effects on hemodynamic properties of the large arteries. Arterial stiffness, while being firstly determined by traditional risk factors for cardiovascular disease, can be influenced by passive mechanisms that consider mechanical and elastic properties of the vessels, and active mechanisms, regulated by the cellular and molecular function of the endothelium, the vascular smooth cells, and the extracellular matrix \[[@B1]\]. Some of these mechanisms may be influenced by n-3 PUFA intake.

Arterial blood pressure is considered the main determinant of arterial stiffness \[[@B9]\]. A fundamental mechanical property of the arteries is that the arterial wall becomes stiffer when the distending pressure becomes higher. Hypertension can also increase arterial stiffness chronically, by inducing elastin fragmentation and arterial wall remodeling \[[@B31]\]. A large body of studies demonstrated that n-3 PUFA are able to reduce systemic blood pressure \[[@B32]\], and a recent meta-analysis confirmed that a consumption of \>2 g/d of EPA + DHA can reduce systolic and diastolic blood pressure in humans \[[@B33]\]. Thus, blood pressure, a main factor associated with arterial stiffening, is influenced by n-3 PUFA intake, explaining part of the beneficial effect of fatty acids on the arterial wall.

Triglyceride levels are known to be affected by n-3 PUFA intake. A supplementation of 2-3 g/d of EPA + DHA can reduce triglyceride levels by 25--30%, although a slight increase of LDL levels was observed in some studies \[[@B34]\]. Lipid abnormalities are well-known determinants for the development of atherosclerotic vessels disease and related abnormalities, such the stiffening of large arteries. In large cross-sectional studies \[[@B35]\] triglyceride levels were strongly associated with arterial properties, although a specific benefit in arterial stiffness levels with therapies targeting triglycerides has not been demonstrated yet.

Elevated heart rate has been shown to be associated with an increased risk of cardiovascular events, and there is evidence that the heart rate is independently associated with the progression of arterial stiffness, both in animal models and in humans \[[@B36]\]. n-3 PUFA supplementation is able to reduce resting heart rate and recovery after exercise. Experimental studies suggested that heart rate lowering could result from direct effects on cardiac electrophysiology \[[@B37], [@B38]\]. Some studies also suggested that n-3 PUFA might improve neurogenic autonomic function of cardiovascular system, through a modulation of vagal and sympathetic balance \[[@B39]\], and an independent association between aortic stiffness and muscle sympathetic nerve activity has been reported \[[@B40]\].

The effect of n-3 PUFA on classical risk factors for cardiovascular disease may explain the favorable effect on arterial stiffness. Nevertheless other mechanisms, mediated through biochemical cellular signaling and through neurogenic and neuroendocrine pathways, have been explored. The association between endothelial dysfunction and increased arterial stiffness has been demonstrated in vitro \[[@B41]\] and in vivo, both in animals and in humans \[[@B42], [@B43]\]. Considering the known effect of n-3 PUFA on endothelial function, which is discussed later in this review, this could be a main explanation of the reduction of arterial stiffness observed in experimental condition of n-3 PUFA supplementation. An enhancement in endothelial-dependent vasodilation of the muscular arterioles leads to a decrease in arterial stiffness because mechanical stresses are transferred to elastin components of the wall and because there is a reduction in reflected pulse waves \[[@B44]\]. A direct vasodilatory effect and an inhibition of constrictor response of DHA have been demonstrated in humans \[[@B45]\]. An interrelation of this vasodilatory effect has been found with different endocrine pathways, as the vascular constrictor response to angiotensin \[[@B46]\] and norepinephrine \[[@B47]\] is attenuated by n-3 PUFA in humans.

Therefore, the improvement in arterial properties shown after n-3 PUFA supplementation is multifactorial and involves both passive and active mechanisms of arterial hemodynamics, mediated by multiple cellular and molecular pathways and influenced by some major cardiovascular risk factors (hypertension, blood lipids, and autonomic balance).

5. n-3 PUFA and Arterial Stiffness: In Vivo Studies {#sec5}
===================================================

Many studies have focused directly on the evaluation of arterial stiffness after n-3 PUFA supplementation ([Table 1](#tab1){ref-type="table"}). Considering animal models, Sato et al. \[[@B48]\] found that supplementation of EPA reduced aortic PWV in high-cholesterol-diet-fed rabbits. Masson et al. \[[@B49]\] reported that pulse pressure obtained from telemetry, an index of arterial stiffness, was reduced by n-3 PUFA in fructose-fed rats, a model of insulin-resistant state. Similarly, Engler et al. \[[@B50]\] demonstrated that DHA supplementation reduced pulse pressure and vascular wall thickness in spontaneously hypertensive rats. More recently our group demonstrated that n-3 PUFA supplementation prevents arterial stiffening \[[@B51]\] and other vascular changes, such as baroreflex sensitivity \[[@B52]\] induced by ovariectomy, in a rat experimental model of menopause.

A number of randomized and controlled clinical trials have been conducted to explore the effects of n-3 PUFA on various endpoints related to arterial stiffness. A well-conducted meta-analysis by Pase et al. in 2011 \[[@B53]\], considering 10 intervention trials of n-3 PUFA supplementation, reported that the 2 main outcomes examined (PWV and systemic arterial compliance) were favorably affected by the intervention, thus providing strong support to the use of n-3 PUFA as an evidence-based mean to reduce arterial stiffness. The randomized clinical trials considered in this meta-analysis considered mainly high risk patients, with cardiovascular risk factors ranging from dyslipidemia, hypertension, and obesity to type 2 diabetes. More recent trials confirmed this result with the validated endpoint of carotid-femoral PWV, actually considered the gold standard measure for arterial stiffness \[[@B9]\]. These studies, performed in special patient population such as healthy smokers \[[@B54]\] and metabolic syndrome patients \[[@B55]\], confirmed a reduction in arterial stiffness. A large study conducted evaluating carotid-radial PWV in elderly men with hypercholesterolemia \[[@B29]\] and systemic arterial compliance in obese patients on a weight loss diet \[[@B56]\] confirmed a favorable effect in arterial stiffness. Considering innovative measurement methods of arterial stiffness, a small open-label study observed an improvement in regional aortic stiffness assessed by strain rate, using tissue Doppler imaging \[[@B57]\]. Three randomized clinical trials conducted with small doses of n-3 PUFA (\<1.8 g/d) on healthy patients \[[@B58]\] and on young healthy patients with metabolic syndrome \[[@B59]\] or obesity \[[@B60]\] did not find any significant effect on arterial stiffness. In a trial evaluating patients with cardiovascular risk factors a fish oil diet was ineffective in reducing brachial-ankle pulse wave velocity, while the subsequent administration of pure EPA in the same population significantly reduced the arterial stiffness \[[@B61]\]. Considering cross-sectional studies, in general Japanese population, there was no relationship between serum omega-3 levels and arterial stiffness, evaluated as brachial-ankle PWV \[[@B62]\], while in a sample of 299 Korean men a regression analysis found a significant inverse association with total n-3 PUFA and carotid-femoral PWV \[[@B63]\].

Despite the few negative results in randomized clinical trials, current evidences generally agree that n-3 PUFA are effective in reducing arterial stiffness in humans. We can speculate that the negative results in these trials \[[@B58]--[@B60]\] are due to the small dose of active treatment or to the fact that in these trials a population with a low risk for cardiovascular disease was considered (young patients, healthy volunteers). The preferred use of n-3 PUFA only in high risk patients or in secondary prevention is supported by current guidelines and could be applied also for n-3 PUFA administration for the purpose of reducing arterial stiffness, although well-designed clinical trials considering high and low risk population are needed to support this evidence.

As arterial stiffness is a strong risk factor for cardiovascular disease, n-3 PUFA should be considered, among the wide range of cardiovascular drugs, as a safe and evidence-based choice to positively affect the mechanical properties of arterial wall. Which dose is the best for this outcome and which group of patients should be treated constitute an important area of future research.

6. Regulation of Endothelial Function and Endothelial Dysfunction {#sec6}
=================================================================

Classically the term "endothelial dysfunction" strictly refers to reduced endothelium-dependent vasodilation, which is notably associated with impaired bioavailability of the main endothelium-derived relaxing factor, nitric oxide (NO). In addition to promoting vasodilation, NO is a powerful antiatherosclerotic agent, since it reduces leukocyte adhesion, platelet aggregation, and smooth muscle cell proliferation \[[@B64]\]. In the endothelium NO is produced by the enzyme endothelial nitric oxide synthase (eNOS). Reduced nitric oxide bioavailability can be the result of either decreased production or increased scavenging. Several mechanisms, including downregulation of eNOS expression, posttranslational modifications of eNOS, inhibition of the enzyme catalytic activity, enzyme uncoupling, and circulating eNOS inhibitors result in decreased NO release and endothelial dysfunction \[[@B65], [@B66]\].

On the other hand, a number of studies have shown that reactive oxygen species (ROS), which are increased in many conditions associated with enhanced oxidative stress, determine endothelial dysfunction by quenching NO, reducing its bioavailability and leading to the formation of the highly toxic peroxynitrite \[[@B66], [@B67]\].

Perturbations of NO bioavailability are usually associated with signs of vascular inflammation and of a prothrombotic and procoagulable state \[[@B68]\]. Therefore, in a comprehensive sense, the term endothelial dysfunction encompasses a wide range of alterations of endothelial function preluding overt atherosclerosis.

Endothelial dysfunction is typically detected in conditions associated with vascular disease, such as hypertension, smoking, diabetes mellitus, hypercholesterolemia, and aging \[[@B69]\]. Clinically, endothelial dysfunction can be noninvasively assessed by measuring flow-mediated dilation (FMD), at the level of the brachial artery or of the coronary bed. This parameter allows determining the capability of the vessel to dilate in response to various stimuli (hyperemia following sphygmomanometer cuff inflation or infusion of muscarinic receptor agonists) \[[@B4], [@B70]\]. Importantly, several studies have demonstrated the prognostic value of endothelial dysfunction in terms of future cardiovascular events in both populations at low and high cardiovascular risk, its predictive value being not inferior to validated surrogate markers of vascular function \[[@B4], [@B71]--[@B73]\]. Therefore endothelial dysfunction can be considered an early marker of increased cardiovascular risk in patients with or without a previous history of cardiovascular disease.

7. Influence of n-3 PUFA on Endothelial Function {#sec7}
================================================

The mechanism by which n-3 PUFA influence endothelial function is mediated by their incorporation into biological membrane phospholipids; this allows modulation of membrane composition and fluidity. The importance of endothelial cell membrane composition has been documented by several studies ([Table 2](#tab2){ref-type="table"}). The reason lies in the fact that endothelial cell membrane houses caveolae and lipid rafts where several receptors and signaling molecules crucial for cell function are concentrated \[[@B74]\]. Caveolae-associated receptor-mediated cellular signal transduction includes important pathways such as the nitric-oxide cGMP pathway, the NADPH oxidase and TNF-*α* --NF*κ*B induced cyclooxygenase-2 (COX-2) and prostaglandin E~2~ (PGE~2~) activation pathway \[[@B75], [@B76]\]. By modulating the composition of caveolae, as described for other classes of lipids \[[@B77]\] n-3 PUFA may exert their beneficial effects, which include increased NO production and reduced production proinflammatory mediators.

Molecular evidence of enhanced eNOS activity/expression following administration of n-3 PUFA derives from experimental studies in endothelial cells in culture or in animals. Wu et al. \[[@B78]\] showed that in bovine aortic endothelial cells and in eNOS knock-out mice EPA induces NO production by stimulating AMP-activated protein kinase (AMPK) induced endothelial nitric oxide synthase (eNOS) activation. Similarly, Omura et al. demonstrated that EPA stimulates eNOS activation in endothelial cells by inducing its dissociation from the inhibitory scaffolding protein caveolin \[[@B79]\]. Likewise, Stebbins et al. reported that DHA promotes eNOS activity by increasing the interaction between eNOS and HSP-90, which activates PKB/AKt pathway finally resulting in eNOS phosphorylation and activation \[[@B80]\]. Finally, n-3 PUFA can enhance eNOS activity by reducing the circulating levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of eNOS, which is increased in conditions as hypertension, renal failure, and aging \[[@B81]\].

Another mechanism by which n-3 PUFA increase NO production is by directly stimulating eNOS gene and protein expression. Improved vasodilation as a result of n-3 PUFA induced upregulation of eNOS gene/protein expression has been documented in a wide series of reports considering physiological and disease animal models including menopause, atherosclerosis, and diabetes mellitus by our and other groups \[[@B82]--[@B88]\]. Taken together these data indicate a strong potential of n-3 PUFA to potentiate NO availability by enhancing its production via different molecular mechanisms.

In addition to increasing NO production, n-3 PUFA decrease oxidative stress. This effect is controversial, since the prooxidant activity of long-chain n-3 PUFA especially at high doses has long been debated \[[@B89]\]. However experimental studies conducted so far in cell culture or in vascular beds of experimental animals have shown that relatively large doses of n-3 PUFA improve endothelial function by attenuating ROS production as a result of a direct modulatory effect on the sources of ROS formation, including the enzymes NADPH oxidase and iNOS, finally resulting in reduced peroxynitrite formation \[[@B82], [@B83]\]. In retinal endothelial cells in culture exposed to high glucose ALA directly reduces ROS information and increased superoxide dismutase (SOD) activity \[[@B90], [@B91]\]. A potentiation of endogenous antioxidant enzyme concentrations in plasma as a direct effect of n-3 PUFA oral administration has also been reported also by other reports \[[@B92]\].

Among the contributors to endothelial dysfunction, n-3 PUFA have shown the potential to attenuate cellular and systemic inflammation. In endothelial cells in vitro n-3 PUFA attenuate NF-*κ*B activation, resulting in reduced VCAM-1 expression \[[@B90]\]. Additionally, n-3 PUFA exert systemic anti-inflammatory effects by raising the plasma levels of adiponectin \[[@B93]\] and suppressing the production of interleukin 6, interleukin 1*β*, soluble E selectin, and CRP \[[@B94]\]. These effects are dose-dependent, as relatively high doses of n-3 PUFA are required to achieve the anti-inflammatory effect and this cannot exclude the fact that indirectly also the triglyceride-lowering effect contributes to improved endothelial function often observed in these conditions.

8. n-3 PUFA and Endothelial Dysfunction: In Vivo Human Studies {#sec8}
==============================================================

n-3 PUFA show the potential to improve endothelial dysfunction by activating NO production via different mechanisms and by reducing vascular oxidative stress and inflammation ([Figure 1](#fig1){ref-type="fig"}). Many studies have evaluated the effect of n-3 PUFA on human endothelial function and the results have been reported by two recent meta-analyses \[[@B95], [@B96]\], whose conclusions are not completely concordant. For review reasons, we will focus on studies published during the last 5 years. One issue that needs to be considered when evaluating the effect of n-3 PUFA supplementation on endothelial function is the poverty of data on n-3 PUFA basal enrichment in the patient population under consideration. The amount of n-3 PUFA in biological membranes can be directly extrapolated by measuring the omega-3 index in red blood cell membranes \[[@B97], [@B98]\] or by determining plasma concentrations of EPA + DHA which have shown a good correlation with their membrane levels \[[@B89]\]. This point is crucial as conditions characterized by n-3 PUFA depletion may mostly benefit from their supplementation. In a recent study conducted in an experimental model of menopause, deficiency of n-3 PUFA demonstrated by low omega-3 index was associated with endothelial dysfunction and increased oxidative stress, which were reversed by efficient n-3 PUFA supplementation, resulting in normalization of omega-3 index \[[@B82]\]. Having said this, clinical trials on the effects of n-3 PUFA on endothelial function are significantly heterogeneous innumber of included participants;inclusion criteria: age of participants, healthy or disease state, have been studied;markers of endothelial function: in addition to flow-mediated dilation, at least 7 different classes of surrogate markers have been tested in the last 5 years. The most frequent categories tested, according to their different pathophysiological roles, are proinflammatory and anti-inflammatory cytokines, endothelial progenitor cells, markers of platelet activation, of fibrinolysis, of thrombosis, and of coagulation, and markers of oxidative stress \[[@B98]--[@B102]\];dose and duration of treatment: doses ranging from 0.45 up to 4 grams have been tested as well as treatments ranging from 4 to 52 weeks \[[@B58], [@B103], [@B104]\];forms of n-3 PUFA: EPA, DHA, or ALA has been administered alone or in combination;concomitant therapy: most of the studies on disease states do not provide accurate information on concomitant therapy, particularly on drugs known to improve endothelial function such as statins and ACE inhibitors/angiotensin receptor blockers. The presence of a robust concomitant therapy might improve endothelial function independently of n-3 PUFA (especially at low doses) in high risk patients.So far, most studies have cautiously suggested that supplementation with n-3 PUFA might improve endothelial function. However, whether the amplitude of this effect depends on healthy or disease state or on the administered dose or whether the n-3 PUFA composition of supplementation differentially affects the outcome is currently unclear. In smokers, where the bias of concomitant therapies is not an issue, two recent studies have shown that n-3 PUFA supplementation for six and twelve weeks, respectively, improves endothelial function \[[@B54], [@B105]\]. In patients with moderate cardiovascular risk Seely et al. performed a meta-analysis where again quality and power of the available studies precluded any definite conclusion \[[@B106]\]. However, low-strength evidence seemed to suggest a benefit of n-3 PUFA in endothelial dysfunction. Similar results have been reported in high risk patients with previous myocardial infarction \[[@B104]\] although a recent comprehensive meta-analysis and a recent study in a similar population do not confirm these findings \[[@B107], [@B108]\].

When considering moderate/high risk patients assuming polytherapy, the issue of cost/benefit in terms of clinical efficiency and potential harms is important. Therefore, stronger evidence is needed before large scale prescription of n-3 PUFA in this population.

9. Endothelial-Independent Vasodilation and n-3 PUFA {#sec9}
====================================================

Technically, flow-mediated dilation is the result of both endothelial-derived vasodilation (which is mainly NO-dependent) and endothelial-independent vasorelaxation. The latter depends on the ability of smooth muscle cells to respond to nitric oxide and therefore measures the integrity of arterial media. The hypotensive effect of n-3 PUFA can partly be explained by this mechanism. Therefore, when measuring FMD in vivo in humans, it is difficult to dissect the relative contribution of endothelium and smooth muscle cells unless a selective agonist is administered (muscarinic receptor agonist for EDD and NO donor for EID). A recent study addressed the physiologic mechanisms of EPA-induced relaxation in pulmonary arteries from an animal model \[[@B109]\] and showed that in these conditions the contribution of endothelium-derived NO release to vasodilation is prominent, while that mediated by endothelium-independent mechanisms is negligible.

These findings are in line with data from human studies, showing that when controlled trials assessing EID are considered, no significant effect of n-3 PUFA on EID is observed \[[@B96]\].

10. Conclusive Remarks {#sec10}
======================

By targeting both arterial wall stiffness and endothelial dysfunction n-3 PUFA have the potential to beneficially impact arterial wall remodeling and cardiovascular outcomes. Their pleiotropic effects on systemic inflammation, modulation of lipid profile, and platelet aggregation contribute to the reduction of cardiovascular risk. Although dissecting the specific contribution of structural arterial remodeling to overall cardiovascular risk is difficult from experimental studies conducted in high risk populations, current results are encouraging. From here comes the need for large scale trials, advocated by most of the available literature. This process is likely to involve selection of homogenous patient populations in terms of target disease, endpoints, and modality of treatment.
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###### 

Studies evaluating n-3 PUFA effects on arterial stiffness.

###### 

\(a\) Animal studies

  First author         Year   Dose                                   Sample                              Duration (w)   Study design   Outcome measure      Results
  -------------------- ------ -------------------------------------- ----------------------------------- -------------- -------------- -------------------- ------------------------------
  Sato \[[@B48]\]      1993   300 mg/kg/day EPA                      High-cholesterol-diet-fed rabbits   12             AES-PG         cf-PWV               Prevent increase in cf-PWV
                                                                                                                                                            
  Engler \[[@B50]\]    2003   DHA-enriched oil                       Spontaneous hypertensive rats       6              AES-PG         Wall thickness, PP   Reduce wall thickness and PP
                                                                                                                                                            
  Masson \[[@B49]\]    2008   diet enriched w. 16 g/kg n-3 PUFA      Fructose-fed rats                   10             AES-PC         PP                   Prevent increase in PP
                                                                                                                                                            
  Losurdo \[[@B51]\]   2014   0.65 g/kg/d versus placebo by gavage   Ovariectomized rats                 8              AES-PC         cf-PWV               Prevent increase in cf-PWV

###### 

\(b\) Human studies

  First author           Year   Dose                                                              Sample                                   Duration (w)   Number   Study design   Outcome measure                              Results
  ---------------------- ------ ----------------------------------------------------------------- ---------------------------------------- -------------- -------- -------------- -------------------------------------------- ----------------------------------------
  McVeigh \[[@B110]\]    1994   1800 mg EPA + 1200 mg DHA/d versus placebo (olive oil)            Type 2 diabetes                          6              20       RCT-PC         Total AC                                     Increase in total AC
                                                                                                                                                                                                                               
  Nestel \[[@B111]\]     2002   3000 mg EPA/d versus 3000 mg DHA/d versus placebo (olive oil)     Dyslipidemic                             7              38       RCT-PC         Total AC                                     Increase 36% with EPA, 27% with DHA
                                                                                                                                                                                                                               
  Tomiyama \[[@B62]\]    2011   1800 mg EPA/d versus control (diet therapy)                       Dyslipidemic                             52             84       RCT-PG         ba-PWV                                       Reduction of ba-PWV
                                                                                                                                                                                                                               
  Hjerkinn \[[@B29]\]    2006   2400 mg n-3 PUFA versus control diet                              Dyslipidemic                             156            563      RCT-PG         cr-PWV                                       Decrease in cr-PWV 4%
                                                                                                                                                                                                                               
  Hill \[[@B112]\]       2007   1560 mg DHA + 360 mg EPA/d versus placebo (6 g sunflower oil/d)   Overweight, hypertensive, dyslipidemic   6 to 12        38       RCT-PC         Small and large AC                           Increase in small AC 26%.
                                                                                                                                                                                                                               
  Mita \[[@B28]\]        2007   1800 mg EPA/d versus control (no EPA)                             Type 2 diabetes                          6              64       RCT-PG         ba-PWV                                       Reduction of ba-PWV
                                                                                                                                                                                                                               
  Wang \[[@B113]\]       2008   540 mg EPA + 360 mg DHA versus placebo capsules                   Overweight, hypertensive                 8              52       RCT-PC         Small and large AC                           Increase in large AC 21%
                                                                                                                                                                                                                               
  Satoh \[[@B114]\]      2009   1800 mg EPA/d + diet versus control (diet only)                   Metabolic syndrome                       12             92       RCT-PG         ca-PWV                                       Reduction of ca-PWV 6%
                                                                                                                                                                                                                               
  Ayer \[[@B115]\]       2009   32 mg EPA/d + 135 mg DHA/d + canola oil versus control diet       Healthy children                         260            616      RCT-PG         Carotid artery distensibility, cb-PWV, Aix   No difference
                                                                                                                                                                                                                               
  Sjoberg \[[@B116]\]    2010   1560 DHA + 360 mg EPA/d versus placebo (sunola oil)               Overweight                               12             67       RCT-PC         Small and large AC                           Increase in large AC 14%
                                                                                                                                                                                                                               
  Dangardt \[[@B60]\]    2010   1200 mg n-3 PUFA versus placebo                                   Obese adolescents                        12             25       RCT-PC         cf-PWV                                       No difference
                                                                                                                                                                                                                               
  Sanders \[[@B58]\]     2011   1800 mg n-3 PUFA versus placebo                                   Healthy subjects                         52             312      RCT-PC         cf-PWV                                       Decrease in cf-PWV
                                                                                                                                                                                                                               
  Haiden \[[@B57]\]      2012   1800 mg n-3 PUFA versus placebo                                   Hypertensive, dyslipidemic               52             19       CT             ba-PWV, aortic strain rate                   Decrease in ba-PWV 1%, strain rate 17%
                                                                                                                                                                                                                               
  Siasos \[[@B54]\]      2013   2000 mg n-3 PUFA versus placebo                                   Healthy smokers                          12             20       RCT-PC         cf-PWV                                       Decrease in cf-PWV 6%
                                                                                                                                                                                                                               
  Root \[[@B59]\]        2013   1700 mg n-3 PUFA versus placebo                                   Overweight young                         4              30       RCT-PC         cf-PWV                                       No difference
                                                                                                                                                                                                                               
  Wong \[[@B56]\]        2013   4000 mg n-3 PUFA + diet versus diet alone                         Obese                                    12             13       RCT-PC         Small and large AC                           Increase in large AC 20%, small AC 22%
                                                                                                                                                                                                                               
  Tousoulis \[[@B55]\]   2014   2000 mg n-3 PUFA versus placebo                                   Metabolic syndrome                       12             29       RCT-PC         cf-PWV                                       Decrease in cf-PWV 5%

n-3 PUFA, omega-3 polyunsaturated fatty acids; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; PWV, pulse wave velocity; cf, carotid-femoral; ba, brachial-ankle; cr, carotid-radial; PP, pulse pressure; AC, arterial compliance; AES, animal experimental study; RCT, randomized clinical trial; CT, clinical trial; PG, parallel groups; PC, placebo controlled; d, day; w, week.

###### 

Studies evaluating n-3 PUFA effects on endothelial function.

###### 

\(a\) Animal studies

  First author                   Year   Dose                                                                                              Sample                  Duration (w)   Study design   Outcome measure         Results
  ------------------------------ ------ ------------------------------------------------------------------------------------------------- ----------------------- -------------- -------------- ----------------------- ----------------------------------
  Nyby \[[@B84]\]                2005   Diet enriched with 60% fructose and 4.4% n-3 PUFA versus diet with 60% fructose or control diet   Hyperinsulinemic rats   8              AES-PG         EDD, oxidative stress   Improve EDD and oxidative stress
                                                                                                                                                                                                                        
  Matsumoto \[[@B88]\]           2009   300 mg/kg/day EPA versus control diet                                                             Diabetic rats           4              AES-PC         EDD                     Improve EDD
                                                                                                                                                                                                                        
  Zhang \[[@B83]\]               2013   Diet enriched with ALA 500 mg/kg/day versus control diet                                          Type 2 diabetic rats    5              AES-PC         EDD, oxidative stress   Improve EDD and oxidative stress
                                                                                                                                                                                                                        
  Gortan Cappellari \[[@B82]\]   2013   800 mg/kg/day by gavage versus control diet                                                       Ovariectomized rats     8              AES-PC         EDD, oxidative stress   Improve EDD and oxidative stress

###### 

\(b\) Human studies

  First author               Year   Dose                                                                                                      Sample                                  Duration (w)   Number   Study design   Outcome measure                       Results
  -------------------------- ------ --------------------------------------------------------------------------------------------------------- --------------------------------------- -------------- -------- -------------- ------------------------------------- ------------------------------------------------------------------
  Woodman \[[@B117]\]        2003   3800 mg EPA or 3700 mg DHA versus olive oil                                                               Hypertensive type 2 patients            6              30       RCT-PG         EDD, EID                              Unchanged EDD and EID
                                                                                                                                                                                                                                                                   
  Engler \[[@B118]\]         2004   1200 mg n-3 PUFA versus control diet                                                                      Hypercholesterolemic children           10             20       RCT-PC         EDD, oxidative stress, inflammation   Improved EDD, unchanged oxidative stress and inflammation
                                                                                                                                                                                                                                                                   
  Ros \[[@B119]\]            2004   1100--1700 mg n-3 PUFA versus Mediterranean diet                                                          Hypercholesterolemic patients           4              20       RCT-PG         EDD, oxidative stress and CRP         Improved EDD, unchanged oxidative stress and inflammation
                                                                                                                                                                                                                                                                   
  Keogh \[[@B120]\]          2005   4700 mg mg n-3 PUFA versus isocaloric high carbohydrate, saturated or monounsaturated fat enriched-diet   Healthy subjects                        4              40       RCT-PG         EDD, CRP, inflammation                Improved EDD in all groups except in saturated fat enriched diet
                                                                                                                                                                                                                                                                   
  Prabodh Shah \[[@B121]\]   2007   500 mg n-3 PUFA versus placebo                                                                            Healthy subjects                        2              26       RCT-PC         EDD, EID                              Improved EDD and EID
                                                                                                                                                                                                                                                                   
  Wright \[[@B122]\]         2008   3000 mg n-3 PUFA versus standard therapy                                                                  Systemic lupus erythematosus patients   24             56       RCT-PG         EDD, oxidative stress                 Improved EDD and oxidative stress
                                                                                                                                                                                                                                                                   
  Schiano \[[@B123]\]        2008   1700--2000 mg versus standard therapy                                                                     Intermittent claudication patients      13             32       RCT-PG         EDD, inflammation                     Improved EDD, inflammation unchanged
                                                                                                                                                                                                                                                                   
  Mindrescu \[[@B124]\]      2008   4500 mg n-3 PUFA + rosuvastatin 10 g versus rosuvastatin 10 g                                             Dyslipidemic patients                   4              30       RCT-PG         EDD, EID                              Improved EDD and EID
                                                                                                                                                                                                                                                                   
  Rizza \[[@B125]\]          2009   1700--2000 mg n-3 PUFA versus placebo                                                                     Offspring of type 2 diabetic subjects   12             50       RCT-PC         EDD, inflammation                     Improved EDD and inflammation
                                                                                                                                                                                                                                                                   
  Wong \[[@B99]\]            2010   4000 mg n-3 PUFA versus control (olive oil)                                                               Type 2 diabetes mellitus                12             97       RCT-PG         EDD, CRP, renal function              Improved renal function; no effect on EDD or CRP
                                                                                                                                                                                                                                                                   
  Stirban \[[@B100]\]        2010   2000 mg versus control (olive oil)                                                                        Type 2 diabetes mellitus                6              34       RCT-PC         Postprandial EDD                      Improved postprandial EDD
                                                                                                                                                                                                                                                                   
  Sanders \[[@B58]\]         2011   450--900 or 1800 mg n-3 PUFA versus placebo (refined oil)                                                 Healthy subjects                        51             310      RCT-PC         EDD                                   Unchanged EDD and EID
                                                                                                                                                                                                                                                                   
  Skulas-Ray \[[@B101]\]     2011   850 or 3400 mg versus placebo                                                                             Moderate hypertriglyceridemia           8              26       RTC-PC         EDD, IL-6, CRP                        No effect on EDD, IL-6, or CRP
                                                                                                                                                                                                                                                                   
  Moertl \[[@B103]\]         2011   1000 or 4000 mg n-3 PUFA versus placebo                                                                   CHF                                     12             43       RCT-PC         LVEF, EDD, IL-6                       Improved LVEF, EDD, and IL-6
                                                                                                                                                                                                                                                                   
  Haberka \[[@B104]\]        2011   1000 mg n-3 PUFA versus control (standard diet and therapy)                                               Previous AMI                            12             40       RCT-PG         EDD, EID                              Improved EDD; EID unchanged
                                                                                                                                                                                                                                                                   
  Din \[[@B105]\]            2013   2000 mg n-3 PUFA versus placebo                                                                           Cigarette smokers                       6              20       RCT-PC         EDD, P-selectin, CD40L                Improved EDD and P selectin; CD40L unchanged
                                                                                                                                                                                                                                                                   
  Din \[[@B108]\]            2013   2000 mg n-3 PUFA versus placebo                                                                           Previous AMI                            6              20       RCT-PC         EDD, P-selectin, CD40L                No effect

n-3 PUFA, omega-3 polyunsaturated fatty acids; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; EDD, endothelium dependent dilation; EID: endothelium independent dilation; AMI: acute myocardial infarction; CHF: chronic heart failure; LVEF: left ventricular ejection fraction; IL-6: interleukin-6; CRP: C reactive protein; AES, animal experimental study; RCT, randomized clinical trial; CT, clinical trial; PG, parallel groups; PC, placebo controlled; d, day; w, week.
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